Related Experiment Video
Updated: Aug 19, 2025

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
Published on: May 25, 2020
Opioids for treating refractory dyspnea in patients with heart failure: A protocol for systematic review and
Jianguo Lyu1, Xianghong Sun1, Mingming Chen2
1Intensive Care Unit, Shengjing Hospital of China Medical University, Liaoning, China.
Background:
Dyspnea is a hallmark symptom of heart failure. The existing clinical studies have indicated that opioid can effectively improve the clinical symptoms of heart failure patients with dyspnea. However, there has not been any relevant systematic review and meta-analysis. We performed a protocol for systematic review and meta-analysis to evaluate the safety and efficacy of opioid therapy for heart failure patients with refractory dyspnea.
Methods:
We searched 3 foreign electronic databases (Cochrane Library, Embase, Pubmed) and 4 Chinese electronic databases (China National Knowledge Infrastructure, Wang Fang Database, Chinese Biomedical Literature Database and Chinese Scientific Journal Database) to collect potential studies from their inceptions to October 2022. The risk of bias in the included articles was assessed according to the Risk of Bias Assessment Tool in Cochrane Handbook of Systematic Reviews (5th edition). The quality of evidence was assessed by the Grading of Recommendations Assessment, Development and Evaluation approach. Data were analyzed using the RevMan Version 5.4.1.
Results:
This study will evaluate whether opioid is effective and safe for treating refractory dyspnea in patients with heart failure.
Conclusion:
This meta-analysis will provide comprehensive evidence of opioid therapy for heart failure patients with dyspnea.
More Related Videos
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Heart Failure V: Medical Management
Heart Failure Drugs: β-Blockers
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents

